1. Profiling of EBV-Encoded microRNAs in EBV-Associated Hemophagocytic Lymphohistiocytosis
- Author
-
Li Zhang, Junhong Ai, Chen Zhou, Li-Wei Gao, Zhengde Xie, Kunling Shen, and Chunyan Liu
- Subjects
Male ,Epstein-Barr Virus Infections ,Herpesvirus 4, Human ,endocrine system ,CD8-Positive T-Lymphocytes ,medicine.disease_cause ,Polymerase Chain Reaction ,Lymphohistiocytosis, Hemophagocytic ,General Biochemistry, Genetics and Molecular Biology ,CD19 ,hemic and lymphatic diseases ,microRNA ,medicine ,Humans ,Infectious Mononucleosis ,Child ,Epstein–Barr virus infection ,Hemophagocytic lymphohistiocytosis ,Deoxyribonuclease BamHI ,biology ,fungi ,General Medicine ,musculoskeletal system ,medicine.disease ,Epstein–Barr virus ,MicroRNAs ,Treatment Outcome ,Real-time polymerase chain reaction ,Child, Preschool ,Carrier State ,biology.protein ,Cancer research ,RNA, Viral ,Biomarker (medicine) ,Female ,Biomarkers ,hormones, hormone substitutes, and hormone antagonists ,CD8 - Abstract
Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH) is a life-threatening complication of EBV infection. MicroRNAs (miRNAs) were small non-coding RNA, and EBV could encode miRNAs that are involved in the progression of infection. However, the profiles of EBV-miRNAs in EBV-HLH were unknown. Here, we aimed to profile the expression of EBV-miRNAs in children with EBV-HLH by analyzing 44 known EBV-miRNAs, encoded within the BamHI fragment H rightward open reading frame 1 (BHRF1) and the BamHI-A region rightward transcript (BART), in plasma and cellular targets by real-time quantitative PCR. The study included 15 children with EBV-HLH, 15 children with infectious mononucleosis (IM), and 15 healthy controls. CD8(+) T cells were found to be the cellular target of EBV infection in EBV-HLH, while CD19(+) B cells were infected with EBV in IM. We also found the greater levels of several miRNAs encoded by BART in EBV-HLH, compared to those in IM and healthy controls, whereas the levels of BHRF1 miRNAs were lower than those in IM. The profile and pattern of EBV-miRNAs in EBV-HLH indicated that EBV could display type II latency in EBV-HLH. Importantly, the level of plasma miR-BART16-1 continued decreasing during the whole chemotherapy, suggesting that plasma miR-BART16-1 could be a potential biomarker for monitoring EBV-HLH progression. The pathogenesis of EBV-HLH might be attributed to the abundance of EBV-miRNAs in EBV-HLH. These findings help elucidate the roles of EBV miRNAs in EBV-HLH, enabling the understanding of the basis of this disease and providing clues for its treatment.
- Published
- 2015